Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXALGO vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatments are inadequate
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Initial: 8 mg orally every 24 hours for opioid-naive patients; titration based on response; maximum 32 mg daily.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life: approximately 15-18 hours in healthy adults. Steady state is achieved by 3-5 days. In patients with hepatic impairment, half-life may be prolonged up to 24-27 hours.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Hepatic via CYP3A4 to hydromorphone and other inactive metabolites.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal: primarily as hydromorphone-3-glucuronide and unchanged drug (~40% as glucuronide conjugates, ~3% as unchanged hydromorphone). Fecal: minimal. Total renal clearance accounts for ~50% of drug elimination.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Approximately 20-30% bound to plasma proteins (primarily albumin).
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Volume of distribution (Vd): 90-120 L (approx. 1.3-1.7 L/kg), indicating extensive tissue distribution.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Extended-release tablet: approximately 40% oral bioavailability due to first-pass metabolism. Bioavailability relative to immediate-release hydromorphone is comparable.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
GFR 30-59 m L/min: reduce dose by 50%; GFR <30 m L/min: start with 4 mg every 24 hours and titrate cautiously.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh Class A or B: reduce dose by 25-50%; Child-Pugh Class C: avoid use or use with extreme caution with 50% dose reduction.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Not approved for pediatric use; safety and efficacy not established.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Start at lowest dose (4 mg every 24 hours) and titrate slowly due to increased sensitivity and risk of respiratory depression.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Serious, life-threatening, or fatal respiratory depression; risk of opioid addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Respiratory depression; addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; gastrointestinal obstruction; seizure-prone patients; head injury; impaired renal or hepatic function.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydromorphone or any component of the product.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid grapefruit and grapefruit juice as they may increase hydromorphone levels. Avoid alcohol and any food containing alcohol, as it can potentiate CNS depression. No other significant food interactions reported; however, a high-fat meal may delay absorption but does not affect overall exposure.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
FDA Pregnancy Category C. First trimester: Limited data, but opioids cross placenta; risk of neural tube defects not established. Second/third trimester: Prolonged use may cause fetal opioid dependence, neonatal abstinence syndrome (NAS). High doses near delivery may cause neonatal respiratory depression.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Hydromorphone is excreted in breast milk; M/P ratio approximately 2.6. Relative infant dose ~0.5-2% of maternal weight-adjusted dose. Use with caution; monitor infant for sedation, respiratory depression, and withdrawal. Consider risk of infant opioid exposure.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Pregnancy may increase hydromorphone clearance due to increased renal blood flow and hepatic metabolism, potentially requiring higher or more frequent doses to maintain analgesia. However, no established guidelines; individualize dosing based on pain control and signs of respiratory depression. Avoid use during labor due to risk of neonatal respiratory depression.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
EXALGO (hydromorphone extended-release) is an opioid agonist indicated for pain severe enough to require daily, around-the-clock, long-term opioid treatment. Do not crush, chew, or dissolve tablets; this can cause rapid release and fatal overdose. Due to its high potency (5-7 times morphine), initiate cautiously in opioid-naïve patients. Use with naloxone available and educate on signs of respiratory depression. Avoid use in patients with significant respiratory depression, acute or severe bronchial asthma, or known or suspected paralytic ileus. Monitor for opioid-induced constipation and consider bowel regimen. EXALGO's QD dosing is convenient but requires strict adherence to 24-hour interval.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take EXALGO exactly as prescribed; do not take more than prescribed or more often than every 24 hours.,Swallow tablets whole; do not crush, chew, or dissolve them as this can cause a fatal overdose.,Avoid alcohol and any other central nervous system depressants (e.g., benzodiazepines, other opioids) unless directed by your doctor, as they increase risk of severe sedation and respiratory depression.,Store in a safe place out of reach of children and others; dispose of unused tablets via a drug take-back program.,Do not stop taking EXALGO abruptly without consulting your doctor; withdrawal symptoms may occur.,Seek emergency help if you experience trouble breathing, extreme drowsiness, or fainting.,Do not drive or operate heavy machinery until you know how EXALGO affects you.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXALGO vs ACTIQ, answered by our medical review team.
EXALGO is a Opioid Analgesic that works by Mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXALGO and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXALGO is: Initial: 8 mg orally every 24 hours for opioid-naive patients; titration based on response; maximum 32 mg daily.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXALGO and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXALGO is classified as Category C. FDA Pregnancy Category C. First trimester: Limited data, but opioids cross placenta; risk of neural tube defects not established. Second/third trimester: Prolonged use may cause fe. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.